Clinical Trial Update: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluation of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid tumors has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor

Drugs mentioned

• pasireotide long acting release (LAR) (pasireotide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2022-01-18